XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial
|
|
- Paul Rafe O’Neal’
- 5 years ago
- Views:
Transcription
1 XERAVATM (eravacycline): A Novel Fluorocycline Antibacterial Matteo Bassetti, MD, PhD Infectious Diseases Division University of Udine and Santa Maria Misericordia University Hospital Udine, Italy
2 Disclosures Research grants - Astellas, Pfizer, MSD, Gilead Advisor/consultant - Angelini, Astellas, AstraZeneca, Bayer, Basilea, Gilead, Menarini, MSD, Pfizer, Novartis, Shionogi, Vifor, The Medicines company, Tetraphase, Achaogen, Paratek, Melinta, Cidara, Nabriva Speaker/chairman Angelini, Astellas, AstraZeneca, Bayer, Pfizer, MSD, Gilead, Vifor, Novartis, Bayer,Tetraphase,Menarini, Cidara
3 IDSA Calls for 10 new antibiotics by Omadacycline 10. Eravacycline 9. Meropenem/vaborbactam 8. Plazomicin 7. Ceftazidime/Avibactam 6. Ceftolozane/Tazobactam 5. Oritavancin 4. Tedizolid Phosphate 3. Dalbavancin 2. Fidaxomicin IDSA = Infectious Diseases Society of America Ceftaroline Fosamil
4 Eravacycline: A Novel Fluorocycline Novel, fully-synthetic fluorocycline antibiotic Two structural modifications: fluorine at C7 and pyrrolidinoacetamido group at C9 - F O N N H H3C N CH3 H H OH OH OH O OH O NH2 O Retains activity against the most common tetracycline-specific acquired resistance mechanisms (i.e., efflux and ribosomal protection) Binds to the 30S ribosomal subunit, disrupting bacterial protein synthesis XERAVA (eravacycline) [SPC]. Ireland Limited: Tetraphase Pharmaceuticals; 2018 Xiao, et al. J Med Chem. 2012; 55(2): ; Grossman, et al. AAC. 2012; 56(5):
5 Anti-Gram-negative activity of new antibiotics MDR P.aeruginosa MDR Acinetobacter ESBL CRE Cefiderocol Ceftolozane- Tazobactam Ceftazidime-avibactam KPC and NDM-1 NO KPCs and OXA-48 (not active against MBLs) NO NO Ceftaroline fosamilavibactam KPCs and OXA-48 (not active against MBLs) NO NO Aztreonam-avibactam MBLs such as NDM NO Meropenem/vaborbactam Imipenem/cilastatinrelebactam KPCs KPCs and OXA-48 (not active against MBLs) NO^ NO NO Plazomicin most KPCs (not active against many NDMs) NO NO Eravacycline KPCs NO ^Active against P. aeruginosa, but not MDR P. aeruginosa., ESBL: extended-spectrum β-lactamases; KPC: K. pneumoniae carbapenemase; OXA: oxacillinase; MBL: metallo-β-lactamase; MDR: multidrug resistant; NDM: New Delhi metallo-beta-lactamase; CRE: carbapenemase-producing Enterobacteriaceae. Products in yellow are not licensed by EMA (status: phase II or III, pre-registration) Bassetti M et al. Expert Review of Anti-infective Therapy 2017 Jan;15(1):55-65
6 Eravacycline Pharmacokinetics Overview Absorption Mean (%CV) Plasma Exposure of Eravacycline 1 mg/kg After Single and Multiple IV Dose in Healthy Adults Cmax and AUC increased approximately doseproportionally over single-dose IV administration of doses from 1 mg/kg to 3 mg/kg Cmax (ng/ml) AUC0-12 (ng*h/ml) DAY (15) 4305 (14) DAY (16) 6309 (15) Distribution Elimination Mean t is 20 hours Metabolized primarily by CYP3A4- and FMO-mediated oxidation ~34% excreted in urine and 47% in feces as unchanged eravacycline (20% in urine and 17% in feces) and metabolites Protein binding increases with increasing plasma concentrations 79% to 90% bound at plasma concentrations, ranging from 100 to 10,000 ng/ml Vss=321L AUC, area under the curve; Cmax, maximum concentration; CYP, cytochrome P450; t, half-life; Vss, volume of distribution at steady state. XERAVA (eravacycline) [SPC]. Ireland Limited: Tetraphase Pharmaceuticals; 2018
7 Plasma and Intrapulmonary Concentrations of Eravacycline Eravacycline 1.0 mg/kg IV q12h for a total of seven doses Sample Site AUC0-12 (ug-h/ml) Site:Unbound Plasma Ratio Plasma (total) 4.56 Plasma (unbound) 0.77 ELF AM Connors KP, et al. Antimicrob Agents Chemother 2014;58:
8 Eravacycline: Global In vitro Activity Against Gram-negative Pathogens: Surveillance MEM* AMK* PTZ FEP N ERV TGC Acinetobacter baumannii /1 2/4 32/>64 32/>64 >64/>128 >16/>64 Citrobacter spp / /1 0.5/1 2/ /1 Enterobacter spp /1 0.5/1 0.06/0.12 4/ /4 Escherichia coli / / /0.03 2/4 2/ />16 Klebsiella spp / /2 0.03/0.06 2/ /4 Proteus mirabilis 984 4/8 0.06/0.12 2/4 0.5/1 0.25/1 Serratia marcescens /0.12 2/4 2/ /0.5 Organism AMK: amikacin, ERV: eravacycline, FEP: cefepime, TGC: tigecycline, MEM: Meropenem, PTZ; piperacillin/tazobactam, MIC 50/90 units are in mcg/ml * = was not tested during all years In vitro activity does not necessarily correlate with clinical efficacy Data on file Tetraphase Pharmaceuticals. Watertown, MA
9 Eravacycline: Global In vitro Activity Against Gram-positive Pathogens: Surveillance Organism Enterococcus faecalis VRE faecalis Enterococcus faecium VRE faecium Staphylococcus aureus MRSA Streptococcus anginosis group N ERV TGC LIN VAN* AMP* / / / /0.25 > / /0.25 1/>32 > / /0.25 >32 > / /0.25 1/1 NT / /0.25 1/1 NT /0.06 NT NT NT NT AMP: ampicillin, ERV: eravacycline, TGC: tigecycline, LIN, Linezolid; VAN, vancomycin; MRSA: methicillin-resistant S. aureus, VRE: vancomycin-resistant enterococci; units are in mcg/ml, * = was not tested during all years In vitro activity does not necessarily correlate with clinical efficacy Data on file Tetraphase Pharmaceuticals. Watertown, MA
10 Eravacycline: In vitro Activity Against Anaerobic Pathogens N ERV TGC CLI MTZ Bacteroides fragilis /2 0.5/8 2/>128 <1/1 Bacteroides caccae /2 1/8 8/128 Bacteroides thetaiotamicron /2 1/8 8/>128 <1/1 Clostridium difficile /0.06 <0.06/0.25 4/ /0.5 Clostridium perfringens / /2 1/>8 < Prevotella spp / /2 1/>8 < Organism ERV: eravacycline, CLI: clindamycin, TGC: tigecycline, MTZ: metronidazole, units are in mcg/ml In vitro activity does not necessarily correlate with clinical efficacy Snydman D, et al. Antimicro Agents Chemother 2018;62(5):e , Goldstein EC, et al. Anaerobe 2018;4:122-4, Morrissey I, et al. Presented at ID Week 2015, San Diego, CA
11 In vitro activity of eravacycline and comparators in Enterobacteriaceae, including subgroups of strains with an ESBL and a carbapenemresistant phenotype, isolated from patients in the EU Organism Escherichia coli E. coli ESBL Klebsiella oxytoca K. oxytoca ESBL Klebsiella pneumoniae K. pneumoniae ESBL K. pneumoniae CRE Proteus mirabilis P. mirabilis ESBL P. mirabilis CRE Serratia marcescens S. marcescens ESBL S. marcescens CRE Proteus vulgaris P. vulgaris ESBL P. vulgaris CRE N ERV (mg/l) 0.12/ / / /2 0.5/1 0.5/1 0.5/1 2/4 4/4 1/1 1/1 1/1 MIC range (mg/l) / (mg/l) 0.25/ / / /2 4/4 4/8 4/8 2/4 4/4 2/4 2/4 Bassetti M et al. ECCMID 2016; TIG MIC range (mg/l) %S
12 Phase 3 IGNITE Program Investigating Gram-Negative Infections Treated with Eravacycline IGNITE-1-4 IGNITE-2-3 Complicated Complicated Intra-Abdominal Infections Urinary Tract Infections
13 ERV vs LEVO in cuti IV eravacycline failed to meet the FDA primary endpoint (responder rate at end of care[eoc]) using a 10% non-inferiority margin (-10% CI: -14.1%, -6.0%).
14 IGNITE1 and IGNITE4: Study Design IGNITE: Investigating Gram-Negative Infections Treated With Eravacycline POST-TREATMENT EVALUATIONS NONINFERIORITY TRIAL (NI margin: IGNITE1 10%, IGNITE4-12.5%) Eravacycline 1 mg/kg IV q12h IGNITE1: N=541 (1:1) IGNITE4: N=500 (1:1) Primary Endpoint Test of Cure Secondary Endpoint Long-term follow-up DAYS DAYS to 14-Day Dosing Period IGNITE1: Ertapenem 1 g IV q24h IGNITE4: Meropenem 1 g IV q8h DAYS 1-14 Secondary Endpoint End of therapy The design of both studies adhered to both the FDA and EMA development guidance Solomkin J, et al. JAMA Surg. 2017;152(3): ; Tsai et al., Presented at ECCMID 2018, Madrid, Spain
15 IGNITE1/4: Demographics ITT/MITT Population IGNITE1 ITT Population IGNITE4 MITT Population Gender, male, n% ERV (N = 270) 156 (57.8) ETP (N = 271) 163 (60.1) ERV (N = 250) 139 (55.6) MEM (N = 249) 129 (51.8) Race, White, n% 263 (97.4) 260 (95.9) 249 (99.6) 249 (100) 182 (67.4) 195 (72) 180 (72) 174 (69.9) 65 to (23) 44 (16.2) 50 (20) 48 (19.3) (9.6) 32 (11.8) 20 (8) 27 (10.8) (5.66) (5.01) (5.53) (4.88) < 10 (%) 235 (87.0) 221 (81.5) 220 (88) 210 (84.3) (%) 28 (10.4) 40 (14.8) 27 (10.8) 31 (12.4) (%) 4 (1.5) 5 (1.8) 3 (1.2) 7 (2.8) (%) 0 1 (0.4) 0 1 (0.4) 1 (0.4) Age, Mean, y (SD) <65 Body mass index, kg/m2, mean (SD) Baseline APACHE II category, n (%) >25 (%) ERV: Eravacycline, ETP: Ertapenem, MEM: Meropenem Solomkin J, et al. JAMA Surg. 2017;152(3): ; Tsai et al., Presented at ECCMID 2018, Madrid, Spain
16 IGNITE1/4 Baseline Pathogen Distribution micro-itt Population 2717 total baseline isolates 3.6 isolates/patient Newman, et al. Presented at IDWeek 2018, San Francisco, CA
17 IGNITE1/4: 1o Efficacy Endpoint (FDA) Clinical Response at TOC micro-itt Population 100 Difference % CI, -4.9,3.6 Difference % CI, -7.1,5.5 Difference % CI, -6.3,5.3 ERV 1 mg/kg q12h % Clinical Cure % 89.3% 86.8% 87.6% 90.8% 91.2% Eravacycline demonstrated noninferiority to ertapenem and meropenem in the FDA primary analyses Comparator(s) 368/ /431 Pooled Data /226 IGNITE1 (ETP) 177/ /205 Eravacycline achieved high clinical cure rates IGNITE4 (MEM) Clinical Cure (micro-itt Population) ERV: Eravacycline, ETP: Ertapenem, MEM: meropenem; micro-itt: microbiological Intent-to-treat, TOC: Test of Cure Solomkin J, et al. JAMA Surg. 2017;152(3): ; Tsai et al., Presented at ECCMID 2018, Madrid, Spain
18 100 Difference % CI, -4.2, % 90.1% Difference % CI, -7.4,3.8 87% 88.8% Difference % CI, -4.1,5.8 ERV 1 mg/kg q12h 92.4% 91.6% Comparator(s) / /517 Pooled Data 235/ /268 IGNITE1 (ETP) /249 IGNITE4 (MEM) Clinical Cure (MITT Population) Eravacycline demonstrated non-inferiority to ertapenem and meropenem in the EMA primary analyses % Clinical Cure % Clinical Cure IGNITE1/4: 1o Efficacy Endpoint (EMA) Clinical Response at TOC MITT and CE Population 100 Difference % CI, -3.4, % 95.3% Difference % CI, -6.3,2.8 Difference % CI, -2.9, % 94.5% 96.9% 96.1% / /469 Pooled Data / / IGNITE1 (ETP) IGNITE4 (MEM) Clinical Cure (CE Population) Solomkin J, et al. JAMA Surg. 2017;152(3): ; Tsai et al., Presented at ECCMID 2018, Madrid, Spain
19 IGNITE1/4:Per Pathogen Clinical Response at TOC micro-itt Population % Clinical Cure ERV 1 mg/kg q12h Comparator(s) ERV: Eravacycline TOC: Test of Cure Solomkin J, et al. JAMA Surg. 2017;152(3): ; Tsai et al., Presented at ECCMID 2018, Madrid, Spain
20 Clinical and Microbiological Outcomes at TOC in the microitt Population for Subjects with Gram-Negative Bacilli Pathogens Baseline Pathogen Pooled ERV Microbiological cure No. /Total no. (%) Pooled ERV Clinical cure No. /Total No. (%) Pooled Comparator Microbiological cure No./Total No. (%) Pool Comparator Clinical cure No. /Total No. (%) Enterobacteriaceae 277/314 (88.2) 271/314 (86.3) 296/325 (91.1) 289/325 (88.9) CEPH-R& 41/48 (85.4) 43/48 (89.6) 40/45 (88.9) 40/45 (88.9) ESBL confirmed 32/36 (88.9) 32/36 (88.9) 26/29 (89.7) 25/29 (86.2) MDR% 35/46 (84.7) 40/46 (87) 29/32 (90.6) 29/32 (90.6) Acinetobacter baumannii 13/13 (100) 13/13 (100) 7/7/ (100) 7/7 (100) 13/13 (100) 13/13 (100) 5/5/ (100) 5/5 (1000 5/5 (100) 5/5 (100) 1/1 (100) 1/1 (100) 12/12 (100) 12/12 (100) 5/5 (100) 5/5 (100) * CEPH-R& ESBL confirmed MDR% ERV = eravacycline; a = Includes Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Morganella morganii. & = CEPH-R - 3rd/4th-generation cephalosporin-resistant % = MDR = Multidrugresistant.- resistant to at least one member of >=3 antibiotic classes Ditch K et al. Presented at ASM Microbe 2018, Atlanta, GA
21 IGNITE1/4: Selected Adverse Reactions in 1% of Patients Adverse Reactions Eravacycline N = 520 n (%) Comparators N = 517 n (%) Infusion site reactions 40 (7.7) 10 (1.9) Nausea 34 (6.5) 3 (0.6) Vomiting 19 (3.7) 13 (2.5) Diarrhea 12 (2.3) 8 (1.5) Hypotension 7 (1.3) 2 (0.4) Wound dehiscence 7 (1.3) Comparators: ertapenem and meropenem 1 (0.2) Infusion site reactions: catheter/vessel puncture site pain, infusion site extravasation, infusion/injection hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling XERAVA (eravacycline) [SPC]. Ireland Limited: Tetraphase Pharmaceuticals; 2018
22
23 Eravacycline Pros Broad spectrum (Gram+ [MRSA], Gram- [including ESBLs, KPC, NDMs], anaerobes) Acinectobacter Favorable safety and tolerability profile expected Q12-Q24 interval Oral dosing Good lung penetration Con Contraindicated in pregnancy and in children Failed in cuti P3 trial Oral formulation: low bioavailability? Relative to tigecycline: 2-4 more potent; 2 higher AUC AUC, area under the plasma drug concentration-time curve; NDM, New Delhi metallo-β-lactamase
TP Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals
TP-676 Larry Tsai, MD Chief Medical Officer Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals Overview Tetraphase is developing novel antibiotics for serious and life-threatening Gram-negative MDR
More informationAntibiotics to treat multi-drug-resistant bacterial infections
Antibiotics to treat multi-drug-resistant bacterial infections July 2013 JUNE 2013 Copyright 2013 Tetraphase Pharmaceuticals, Inc. 1 Forward Looking Statements and Other Important Cautions Any statements
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationNDA Briefing Document Anti-Infective Drugs Advisory Committee 05 December 2014
CEFTAZIDIME-AVIBACTAM FOR INJECTION for Treatment of Complicated Intra-abdominal Infection (used in combination with metronidazole), Complicated Urinary Tract Infection including Acute Pyelonephritis,
More informationFrequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia
Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia Helio S. Sader, M.D.* Mariana Castanheira, Ph.D. Rodrigo E. Mendes, Ph.D. Robert K. Flamm, Ph.D. JMI
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationNew Antimicrobials: Now and In the Future
New Antimicrobials: Now and In the Future David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School Conflicts of Interest Melinta
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationXerava (eravacycline) NEW PRODUCT SLIDESHOW
Xerava (eravacycline) NEW PRODUCT SLIDESHOW Introduction Brand name: Xerava Generic name: Eravacycline Pharmacological class: Tetracycline antibiotic Strength and Formulation: 50mg; per vial; lyophilized
More informationPaul McGovern, MD Vice President, Clinical Affairs Paratek Pharmaceuticals, Inc. Presented at ECCMID, 22 April 2018, Madrid, Spain.
A phase-3 randomized, double-blind, multicentre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study) Paul McGovern, MD
More informationNew treatments of multidrug-resistant Gram-negative ventilatorassociated
Review Article Page 1 of 22 New treatments of multidrug-resistant Gram-negative ventilatorassociated pneumonia Garyphallia Poulakou 1, Styliani Lagou 1, Drosos E. Karageorgopoulos 2, George Dimopoulos
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationUniversity of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology
University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology This material is supported in part by unrestricted educational
More informationCefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the
More informationAuthor: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents
t Title: In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011 Author: Souha Kanj Andrew Whitelaw
More informationCeftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient Non-Formulary
Ceftolozane/tazobactam (Zerbaxa, Merck) September 2015 Inpatient n-formulary Criteria for Formulary Consideration of Ceftolozane/tazobactam Efficacy Ceftolozane/tazobactam was approved by the Food and
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationHepatitis C Treatment and the Role of the Pharmacist
Infectious Diseases Odds and Ends: Focus on Developments in Hepatology and Gram-Negative Infections Lindsey Childs-Kean, PharmD, MPH, BCPS Clinical Assistant Professor University of Florida College of
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationCHMP extension of indication variation assessment report
23 April 2015 EMA/CHMP/245949/2015 adopted Committee for Medicinal Products for Human Use (CHMP) Invented name: Tygacil International non-proprietary name: TIGECYCLINE Procedure No. EMEA/H/C/000644/II/0092
More informationHealthy Adult cuti Patient. Cmax (mcg/ml)(mean ± SD) 73.7 ± ± 113. Vd (L)(mean ± SD) 17.9 ± ± 12.1
Brand Name: Zemdri Generic Name: plazomicin Manufacturer: Achaogen, Inc Drug Class: aminoglycoside antibacterial Uses: 1-5 Labeled: treatment of complicated urinary tract infections (cuti), including pyelonephritis,
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More informationSusceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)
b r a z j i n f e c t d i s. 2 0 1 3;1 7(6):672 681 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original article Susceptibility rates in Latin American nations: report from
More informationNEW ANTIMICROBIALS. Sarah McClain, PharmD, BCPS Infectious Diseases Pharmacy Resident Carilion Clinic Roanoke Memorial Hospital April 17, 2015
NEW ANTIMICROBIALS Sarah McClain, PharmD, BCPS Infectious Diseases Pharmacy Resident Carilion Clinic Roanoke Memorial Hospital April 17, 2015 DISCLOSURES I have no disclosures or conflicts of interest.
More informationSep Oct Nov Dec Total
LB PAGE 2 LB PAGE 3 Sep Oct Nov Dec 2007 2007 2007 2007 Total Repeat Information Total Repeats 35 15 17 9 76 Repeat Rate 6.01% 0.17% 1.12% 0.39% 2.07% Repeat Chemistry 25 0 2 0 27 Repeat Extraction 1 0
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationAntibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Disclosures. Objectives 3/6/2016. Achaogen: Allergan:
Antibacterial Antibiotic Resistancein 2016 What Should an Internist Know? Michael Satlin, MD, MS Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medicine March 4, 2016 1 Disclosures
More informationBelow is an overview of the oral and poster presentations featuring cefiderocol and S at IDWeek 2017:
SHIONOGI TO HIGHLIGHT RESEARCH ON CEFIDEROCOL (S-649266), A SIDEROPHORE CEPHALOSPORIN, AND S-033188, A CAP-DEPENDENT ENDONUCLEASE INHIBITOR FOR TREATMENT OF INFLUENZA, AT IDWEEK 2017 OSAKA, Japan and FLORHAM
More informationExpert rules in antimicrobial susceptibility testing: State of the art
Expert rules in antimicrobial susceptibility testing: State of the art ESCMID Postgraduate Education Course Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic Hospital Universitario
More informationThis material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.
Division of Medical Microbiology Department of Laboratory Medicine and Pathology University of Alberta Hospital and Stollery Children's Hospital Antibiogram 2006 This material is supported in part by unrestricted
More informationDORIPENEM: THE NEWEST MEMBER OF THE CARBAPENEM FAMILY
Volume 23, Issue 4 January 2008 DORIPENEM: THE NEWEST MEMBER OF THE CARBAPENEM FAMILY as well as for treatment of complicated urinary tract infection (cuti), including pyelonephritis. The following article
More informationOptions for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ.
Options for Complicated Skin and Skin Structure Infections Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator for,
More informationHUSRES Annual Report 2009 Martti Vaara
HUSRES Annual Report 2009 Martti Vaara www.huslab.fi www.intra.hus.fi Martti Vaara, 2/2010 1 The basis of this HUSRES 2009 report is the HUSLAB/Whonet database 2009, which contains susceptibility data
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZERBAXA. Ceftolozane and Tazobactam powder for injection
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZERBAXA Ceftolozane and Tazobactam powder for injection 1.5 gram (g) per vial Containing ceftolozane 1 g (as ceftolozane sulfate) and tazobactam
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationInitial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationPhenotypic detection of ESBLs and carbapenemases
Phenotypic detection of ESBLs and carbapenemases Standardized susceptibility testing residential workshop 2016 Katie Hopkins PhD Clinical Scientist Antimicrobial Resistance and Healthcare Associated Infections
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More information400 mg IV (over 5 to 60 minutes) every 12 hours. > 30 to mg IV (over 5 to 60 minutes ) every 12 hours. 15 to 30
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More informationDIVISION OF ANTIINFECTIVE DRUG PRODUCTS (HFD-520) CLINICAL MICROBIOLOGY REVIEW NDA Date review completed: 15 Jun 05
Date company submitted: 15 Dec 04 Date received by CDER: 15 Dec 04 Reviewer: Fred Marsik, Ph.D. Date assigned: 15 Dec 04 NAME AND ADDRESS OF APPLICANT Wyeth Pharmaceuticals Inc. P.O. Box 8299 Philadelphia,
More informationAntimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2005, p. 3501 3512 Vol. 49, No. 8 0066-4804/05/$08.00 0 doi:10.1128/aac.49.8.3501 3512.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationInnovations in Antimicrobials Something Old, Something New
FSHP Disclosure Innovations in Antimicrobials Something Old, Something New Harrison Bachmeier, PharmD, BCPS Pharmacist Specialist-Infectious Diseases LeeHealth Fort Myers & Cape Coral, FL I do not have
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationAntibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)
Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005) Streptococcus pneumoniae (SP) Blood Culture Isolates Penicillin intermediate Penicillin Cefotaxime 336
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationIn vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria
1 2 In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria 3 4 DAVID M LIVERMORE* 1,2, SHAZAD MUSHTAQ 1, MARINA WARNER 1,, ANNA VICKERS 1 AND NEIL WOODFORD 1 5 6 7 8 1 Antimicrobial
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Doribax 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate
More informationAntibiotics 10 x 20 Progress and Commercial Opportunities
Antibiotics 10 x 20 Progress and Commercial Opportunities i Tim Joslin Managing Director, Europe Defined Health Webinar 15 th February 2012 The information in this presentation has been obtained from what
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationReceived 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1965 1969 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.00203-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparative
More informationVABOMERE (meropenem and vaborbactam) for injection, for intravenous use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VABOMERE safely and effectively. See full prescribing information for VABOMERE. VABOMERE (meropenem
More informationPaul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute
New antimicrobials Paul M. Tulkens Françoise Van Bambeke Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute Université catholique de Louvain,, Brussels, Belgium Slides are
More informationThe role of an AMR reference laboratory
The role of an AMR reference laboratory Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright Primary purpose: regional AMR threats
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationCeftaroline fosamil, as ceftaroline fosamil monoacetate monohydrate.
PRODUCT INFORMATION ZINFORO ceftaroline fosamil NAME OF THE MEDICINE Ceftaroline fosamil, as ceftaroline fosamil monoacetate monohydrate. The chemical name of ceftaroline fosamil monoacetate monohydrate
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationIntroduction. J Antimicrob Chemother 2013; 68 Suppl 2: ii25 ii35 doi: /jac/dkt142
J Antimicrob Chemother 2013; 68 Suppl 2: ii25 ii35 doi:10.1093/jac/dkt142 Efficacy of tigecycline for the treatment of complicated intraabdominal infections in real-life clinical practice from five European
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationVIII Updating Course of Antimicrobials and Infectious Diseases 2018
The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationR EVIEWS OF T HERAPEUTICS
R EVIEWS OF T HERAPEUTICS Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae Sarah Christina Jane Jorgensen, 1 and Michael Joseph Rybak 1,2,3, * 1 Anti-infective
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationEnterobacteriaceae with acquired carbapenemases, 2016
Enterobacteriaceae with acquired carbapenemases, 2016 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationDORIBAX for injection
DORIBAX for injection 500 mg Powder for Intravenous Infusion NAME OF THE MEDICINE Doripenem (as monohydrate) PRODUCT INFORMATION The chemical name for doripenem monohydrate is (4R,5S,6S)-3-[((3S,5S)-5-
More information(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales
(Plasmid mediated) Carbapenemases Timothy R. Walsh, Cardiff University, Wales What is a carbapenemase? How much carbapenem do they need to breakdown before they are called a carbapenemase? ESBL-enzymes
More informationHOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA. Romney Humphries, PhD D(ABMM)
HOW BUGS COMBAT DRUGS: ANTIMICROBIAL RESISTANCE MECHANISMS IN THE MODERN ERA Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu WHAT WE WILL
More informationMolecular β-lactamase characterization of aerobic Gram-negative pathogens recovered from patients
AAC Accepted Manuscript Posted Online 27 March 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02447-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 3 Molecular β-lactamase
More informationYes No Unknown. In hospital Out of hospital Unknown. Blood Pump Drive Unit Failure External Control System Failure. Yes No Unknown
Adverse Events Device Malfunction Was there a device malfunction: Date of event: Was there a device malfunction: Major pump unit involved: Check all the apply Suspected device Thrombosis: Anticoagulant
More informationAchaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti)
Achaogen Launches ZEMDRI (plazomicin), a Once-Daily Aminoglycoside for use in complicated Urinary Tract Infections (cuti) -- ZEMDRI now available for ordering in the U.S. -- -- ZEMDRI demonstrated in vitro
More informationSurveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 41 41 Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia IRINA
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationNAME OF THE MEDICINAL PRODUCT Doribax 500 mg powder for solution for infusion
NAME OF THE MEDICINAL PRODUCT Doribax 500 mg powder for solution for infusion QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate equivalent to 500 mg doripenem. The medicinal
More informationCubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger
Cubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger Cubicin (Daptomycin): A new generation of antibiotics First-in-class cyclic natural lipopeptide Activity against major gram positive pathogens
More informationNEW DEVELOPMENTS AND CHALLENGING CASES IN HOSPITAL INFECTIOUS DISEASES
Lisa G. Winston, MD Professor, University of California, San Francisco Vice Chief, Inpatient Medical Services and Hospital Epidemiologist, San Francisco General Hospital NEW DEVELOPMENTS AND CHALLENGING
More informationAVYCAZ (ceftazidime and avibactam) for injection, for intravenous use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVYCAZ safely and effectively. See full prescribing information
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More informationAVYCAZ (ceftazidime and avibactam) Dosing and Administration
AVYCAZ (ceftazidime and avibactam) Dosing and Administration DOSAGE OF AVYCAZ BY INDICATION IN PATIENTS WITH NORMAL RENAL FUNCTION (CREATININE CLEARANCE GREATER THAN 50 ml/min) 1 DOSAGE ADJUSTMENTS IN
More information